Toxicological evaluations of betulinic acid and ursolic acid; common constituents of Houttuynia cordata used as an anthelmintic by the Naga tribes in North-east India

Mishra, Vijaya; Soren, Amar Deep; Yadav, Arun Kumar

doi:10.1186/s43094-020-00173-4

Future Journal of Pharmaceutical Sciences

Table 7 Effects of sub-acute oral administration of BA and APAP on selected hematological parameters of Wistar rats (n = 5/sex)

From: Toxicological evaluations of betulinic acid and ursolic acid; common constituents of Houttuynia cordata used as an anthelmintic by the Naga tribes in North-east India

Parameters	G-I Control	G-II BA 1 mg/kg	G-III BA 5 mg/kg	G-IV BA 10 mg/kg	G-V APAP 50 mg/kg	Satellite groups
Parameters	G-I Control	G-II BA 1 mg/kg	G-III BA 5 mg/kg	G-IV BA 10 mg/kg	G-V APAP 50 mg/kg	G-VI Control	G-VII BA 10 mg/kg	G-VIII APAP 50 mg/kg
Female
RBC	7.30 ± 0.24	7.82 ± 0.21	7.64 ± 0.12	7.24 ± 0.17	3.21 ± 0.23^a	7.58 ± 0.29	7.89 ± 0.23	7.45 ± 0.21
WBC	7280 ± 386.5	7726 ± 476.3	7100 ± 104.8	7220 ± 0.17	3401 ± 226.6^a	7560 ± 213.6	7441 ± 250.2	7006 ± 107.8
Neut (%)	21.60 ± 3.50	21.80 ± 0.37	23.80 ± 0.37	23.80 ± 1.59	41.80 ± 2.6^a	22.00 ± 2.44	21.00 ± 1.58	19.40 ± 0.67
Lym (%)	36.20 ± 10.5	38.60 ± 11.6	40.40 ± 9.92	62.40 ± 5.9^b	29.80 ± 4.6^a	36.00 ± 2.34	38.00 ± 1.76	38.60 ± 2.42
Eos (%)	2.80 ± 1.11	2.20 ± 0.58	2.80 ± 0.66	5.20 ± 0.58^b	2.00 ± 0.44	2.20 ± 0.37	2.00 ± 0.44	1.60 ± 0.40
Mono (%)	2.20 ± 1.23	2.80 ± 0.58	2.20 ± 0.58	1.80 ± 0.37^a	1.40 ± 0.24^a	2.60 ± 0.24	2.20 ± 0.20	1.40 ± 0.24
PCV (%)	32.41 ± 3.43	40.17 ± 3.34	42.64 ± 1.4^a	42.21 ± 2.1^a	29.91 ± 1.5^a	32.86 ± 1.76	40.49 ± 1.50^c	39.67 ± 0.88
Hb (gm/dL)	12.98 ± 0.47	12.69 ± 0.35	12.56 ± 0.25	12.60 ± 0.27	9.04 ± 0.37^a	12.47 ± 0.34	12.99 ± 0.39	12.15 ± 0.17
Pl (× 10²/cmm)	1863 ± 21.25	1774 ± 43.63	1827 ± 20.21	1783 ± 16.95	1263 ± 30.9^a	1804 ± 30.43	1747 ± 27.08	1632 ± 27.49
Male
RBC	8.20 ± 0.15	8.65 ± 0.38	8.11 ± 0.18	7.73 ± 0.20	3.64 ± 0.13^a	8.11 ± 0.18	8.13 ± 0.25	8.01 ± 0.10
WBC	8540 ± 321.8	8900 ± 130.3	7640 ± 143.5	8078 ± 162.4	5001 ± 298.2^a	8012 ± 355.4	8122 ± 101.08	7948 ± 96.8
Neut (%)	29.60 ± 1.5	30.40 ± 0.67	31.00 ± 0.54	34.80 ± 1.77^a	43.20 ± 2.47^a	29.40 ± 1.36	23.20 ± 1.70	20.60 ± 0.81
Lym (%)	32.00 ± 10.15	38.80 ± 10.24	42.20 ± 6.81^a	60.00 ± 2.09^b	43.20 ± 6.46^a	72.00 ± 2.70	72.20 ± 2.15	63.60 ± 1.56
Eos (%)	2.80 ± 0.37	2.40 ± 0.87	5.80 ± 0.82^b	7.60 ± 0.50^b	1.60 ± 0.40	2.20 ± 0.37	2.00 ± 0.31	1.80 ± 0.37
Mono (%)	2.00 ± 1.00	2.00 ± 0.44	2.40 ± 0.24	2.00 ± 0.54	1.40 ± 0.24^a	1.60 ± 0.40	1.40 ± 0.24	1.60 ± 0.40
PCV (%)	39.19 ± 6.06	44.22 ± 1.48	47.28 ± 0.58	48.04 ± 2.24	30.92 ± 0.84	40.14 ± 3.19	45.10 ± 2.15	43.13 ± 1.19
Hb (gm/dL)	13.68 ± 0.31	12.55 ± 0.33	13.62 ± 0.04	13.58 ± 0.10	9.21 ± 0.13^a	13.36 ± 0.31	13.04 ± 0.32	12.46 ± 0.27
Pl (× 10²/cmm)	1810 ± 33.50	1821 ± 17.24	1826 ± 18.97	1822 ± 20.10	1306 ± 12.47^a	1811 ± 13.24	1803 ± 10.96	1695 ± 43.14

Data are expressed as mean ± SEM; treatment: G-II to G-IV = 4 weeks, G-V to G-VI = 6 weeks
^ap < 0.05, ^bp < 0.01 vs control, one-way ANOVA

Back to article page